热门资讯> 正文
Cue Biopharma Q2 Net Loss Narrows, Revenue Rises
2024-08-20 05:23
05:23 PM EDT, 08/19/2024 (MT Newswires) -- Cue Biopharma (CUE) reported a Q2 net loss late Monday of $0.20 per diluted share, narrowing from a loss of $0.29 a year earlier.
Four analysts polled by Capital IQ expected a loss of $0.27.
Revenue for the quarter ended June 30 was $2.7 million, up from $1.4 million a year earlier. Four analysts surveyed by Capital IQ expected $1.3 million.
Cue Biopharma said its cash and cash equivalents as of June 30 were $30 million down from $48.5 million a year earlier.
Current cash, cash equivalents and marketable securities will fund operations through Q2 2025, according to the company.
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
